Loading organizations...
Founded in 2016 and based in Baar, Switzerland, CorFlow Therapeutics develops the Controlled Flow Infusion System to diagnose and treat microvascular obstruction during percutaneous coronary interventions. This medical device addresses a critical gap in catheter laboratory technologies for STEMI heart attack patients, targeting a market of over 420,000 annual procedures across the United States and Europe. To advance clinical studies and commercialization, the enterprise secured substantial capital, including over 48 million dollars in Series B funding alongside nine million francs in Swiss seed funding and federal grants. The organization is guided by prominent industry veterans, including CEO Paul Mead from Medtronic, Chairman Rick Geoffrion of Cyrano Therapeutics, and cardiologist co-founder Martin. Backed by major venture capital investors like Panakès Partners, the clinical-stage company has achieved significant regulatory milestones such as the FDA Breakthrough Device Designation.
CorFlow Therapeutics has raised $60.3M across 3 funding rounds.
CorFlow Therapeutics has raised $60.3M in total across 3 funding rounds.
CorFlow Therapeutics has raised $60.3M across 3 funding rounds. Most recently, it raised $48.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $48M Series B | Broadview Ventures, Panakes Partners | 415 Capital | Announced |
| Sep 12, 2018 | $9.7M Seed | — | — | Announced |
| Oct 24, 2017 | $2.6M Seed | — | — | Announced |
CorFlow Therapeutics is a Swiss medical technology company that develops innovative diagnostic and therapeutic solutions targeting microvascular disease, particularly microvascular obstruction (MVO) in heart attack patients. Their flagship product, the Controlled Flow Infusion (CoFI™) System, is designed to improve diagnosis and treatment by restoring healthy microvascular blood flow, thereby enhancing cardiac patient outcomes and expanding physician treatment capabilities. The company serves cardiologists and healthcare providers focused on interventional cardiology and vascular medicine, addressing a critical unmet need in managing microvascular complications post-heart attack[1][2][3].
Founded in 2016, CorFlow Therapeutics was co-founded by leading experts in interventional cardiology and medical device development, including a cardiologist with extensive experience at Medtronic. The idea emerged from the recognition of the limitations in current treatments for microvascular obstruction during heart attacks and the need for a device that could both diagnose and therapeutically address this condition. Early traction was built on strong clinical research and the development of the CoFI System, which is rooted in rigorous benchtop science and clinical validation[1][3].
CorFlow Therapeutics operates at the intersection of cardiovascular medicine and medical device innovation, riding the trend of precision diagnostics and targeted therapeutics in cardiology. The timing is critical as microvascular disease is increasingly recognized as a major contributor to adverse outcomes in heart attack patients, yet remains underdiagnosed and undertreated. Market forces such as aging populations, rising cardiovascular disease prevalence, and demand for minimally invasive interventions favor the adoption of technologies like CoFI. By addressing a niche but impactful clinical problem, CorFlow influences the broader ecosystem by pushing forward the standard of care in interventional cardiology and fostering innovation in microvascular diagnostics and therapeutics[1][2][3].
Looking ahead, CorFlow Therapeutics is poised to expand clinical adoption of the CoFI System, potentially broadening its applications beyond cardiac care to other areas where microvascular blood flow restoration is critical. Trends such as personalized medicine, integration of diagnostic and therapeutic devices, and increasing focus on microvascular health will shape their journey. Their influence may grow as they demonstrate improved patient outcomes and cost-effectiveness, potentially becoming a leader in microvascular intervention technologies globally[1][2][3].
CorFlow Therapeutics has raised $60.3M in total across 3 funding rounds.
CorFlow Therapeutics's investors include Broadview Ventures, Panakes Partners, 415 CAPITAL.
